Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
19 March 2019
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards. The chosen world-class research teams are leading the charge towards a cancer free future by investigating new ways to diagnose and treat the disease.
Melanoma Institute Australia researchers, including Co-Medical Directors Professor Georgina Long and Professor Richard Scolyer, Associate Professor Matteo Carlino and Dr James Wilmott, have been awarded Cancer Council NSW Funding of $425,095 over the 2019-2021 funding period. Dr Wilmott attended the Gala Dinner on Thursday, March 14 to formally accept the grant on behalf of Melanoma Institute Australia.
Melanoma of the skin is the fourth most common cancer in Australia, with over 15,000 people expected to be diagnosed with the disease in 2019. Unlike other cancers of the skin, melanoma can spread throughout the body if not treated early. Termed ‘metastatic melanoma’ this advanced form of the disease kills one Australian every 5 hours.
Once melanoma has spread, the most effective treatment is immunotherapy. These immunotherapies release the brakes on the immune system to attack tumour cells. However, more than 40% of metastatic melanoma patients are not cured with these therapies, more for the other cancers. Therefore doctors need to be able to identify who is or isn’t likely to have benefit from the treatment. This means precious time is lost before alternative treatments are offered to those patients for whom immunotherapy won’t be effective.
Dr Wilmott is part of a team of researchers focused on finding treatments for the more than 40% of patients that are not cured with our best current therapies. In another study funded by Cancer Council NSW early career fellowship, the team of oncologists, pathologists, scientists and statisticians identified a set of immune related genes that are critical for a melanoma patient’s response to immunotherapies. The team have initially used these genes to successfully predict the effectiveness of immunotherapy in 105 patients with advanced melanoma.
In this project, the team aim to translate this information from the laboratory into the clinics of their oncology team, giving them the opportunity to test their methods in over 400 patients. They hope to verify their test can accurately identify patients who will respond to standard immunotherapies and the patients for who should be offered alternative treatment options.
This study could lead to the introduction of a simple test in the earliest stages of treatment planning for patients who are diagnosed with advanced melanoma. This would provide critical information for decision-making and ensure patients are offered the treatments most likely to be effective against their cancer.
This was adapted from the article originally published on Cancer Council NSW.
Jay's Longest Melanoma March Trivia Night
Come and join us for a trivia night with Jay and his crew to raise funds for the ABC-X trial!
Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards.
Making a difference to many
Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.
Aussie icon Sophie Monk calls on Australians to get behind Melanoma March
Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
Melanoma breakthrough paves way for personalised treatment for all cancer patients
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March announces 2019 Principal Partner
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
Swimming champion Cate Campbell spearheads national campaign to save lives from melanoma
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA experts collaborate on groundbreaking research
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
World-leading pathologist Associate Professor Michael Tetzlaff visits MIA
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.
Possible PBS listing for dabrafenib and trametinib
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.
Arden Anglican School wins SunSafe Ambassador competition
Three students from Arden Anglican School in Epping have won Melanoma Institute Australia’s (MIA) inaugural SunSafe Student Ambassador Award.
DON'T CLOUD THE SUN-SAFE MESSAGE
Mark Whittaker’s ‘Here comes the sun; Defending our summer rays’ (GW 24 Nov) clouds the sun-safe message – which could have disastrous consequences.
Professor Georgina Long named as one of world's most highly cited researchers
Professor Georgina Long is among only 12 researchers from the University of Sydney to be named in the 2018 Highly Cited Researchers List.
Aussies need to protect themselves from 'everyday' sun damage
‘Wearing sunscreen should be as automatic as wearing a seatbelt. Both are potential life savers.’
The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma
A prestigious $10 million Australian Cancer Research Foundation grant has been awarded to ACEMID, an initiative that aims to use 3D total-body imaging and a remote medicine network to improve the detection and diagnosis of early-stage melanoma.
Major award for world-leaders in melanoma research
Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.
Melanoma Institute Australia shines at prestigious Cancer Research Awards
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
Women of MIA lead the way in melanoma research at SMR
An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.
Immune cell research presented at SMR
Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.
Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.